Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
連絡先
得意分野
Suggested News & Insights
Sidley Represents Apollo Funds in US$4.1 Billion Sale of Kelvion to SLBSeptember 1, 2026Sidley “Highly Recommended” in Latin Lawyer 250 2027August 31, 2026Sidley Represents Mubadala Capital in Its Acquisition of Arrive LogisticsAugust 28, 2026Sidley Represents Bearing Distributors, Inc. in Its Investment From Kelso & CompanyAugust 28, 2026Sidley Represents Valiant Integrated Defense Services on Carve-Out Sale of O&M Division to Inspirit EquityAugust 27, 2026Heightened Means Heightened: Chancery’s First Read of SB 21’s New Presumption Shuts Down Demand FutilityAugust 26, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory